ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer

In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine therapy in premenopausal women. Their discussion also examines the NATALEE PAM50 biomarker analysis, which demonstrated benefit from adjuvant ribociclib across intrinsic molecular breast cancer subtypes without a significant treatment-by-subtype interaction. Together, these findings help clarify how genomic risk assessment, menopausal status, tumor biology, and adjuvant CDK4/6 inhibitor therapy may be integrated into individualized treatment planning and shared decision-making.